Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serhat Sekmek

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 7, 2024
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter studySerhat Sekmek, Irfan Karahan, Gokhan Ucar, et al.
Scientific Reports|November 30, 2024
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studySerhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, et al.
Journal of Clinical Medicine|June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group StudySerhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Scientific Reports|October 9, 2024
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) studyNeslihan Özyurt, Ali Alkan, Burcu Gülbağcı, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 7, 2024
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter studySerhat Sekmek, Irfan Karahan, Gokhan Ucar, et al.
Scientific Reports|November 30, 2024
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studySerhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, et al.
Journal of Clinical Medicine|June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group StudySerhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Scientific Reports|October 9, 2024
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) studyNeslihan Özyurt, Ali Alkan, Burcu Gülbağcı, et al.
Pageof 4